HUMBy Calypso Research8 min read

Humana Inc. (HUM) Q4 2025 Earnings Analysis

Humana's Growth Faces a MA-sive Test Despite 11.3% Revenue Boost

Key Takeaways

Humana Inc. (HUM) reported Q4 2025 earnings with revenue of $32.5B, representing a +11.3% year-over-year change. The stock moved -3.3% on earnings day.

The bull case: Humana’s outsized MA membership growth, combined with CenterWell leverage, cost transformation, capital optimization, and a credible path back to top-quartile STARS, drives a strong recovery in MA margins and EPS toward 2028 targets.

The bear case: Persistent STARS volatility, sub-trend MA funding, cohort integration risk, and the need to support providers and capital levels could keep MA margins depressed longer than expected and prevent Humana from achieving its 2028 earnings and margin ambitions.

Financial Highlights

  • Revenue: $32.5B (+11.3% YoY)
  • Gross Profit: $3.8B (11.7% margin, -1.4% YoY)
  • Operating Income: $-1.0B (-3.2% margin, -0.1% YoY)
  • Net Income: $-796M
  • TTM Revenue: $129.7B

Stock Performance

  • Earnings Day Move: -3.3%
  • Year-to-Date: -31.5%
  • 1-Year Return: -29.0%
  • vs. S&P 500 (since earnings): -28.9%
  • vs. Nasdaq (since earnings): -26.7%

View live HUM data, AI chat, and interactive debates on Calypso →

What Management Said

Here are the key debates and direct quotes from Humana Inc.'s Q4 2025 earnings call:

Sustainability and Profitability of Massive MA Membership Growth (incl. new cohort vs. existing, LTV, and accretion)

Sentiment: Positive

"We expect new members to be enterprise accretive in 2026 on average... More importantly, we expect the membership to drive significant lifetime value further fueling our ability to unlock the earnings potential of the business by 2028." — Celeste Mellet
"Net net, the overall margin for the existing and the new cohorts are fairly consistent but for very different reasons... First, on continuing members, they're disproportionately impacted by the STARS headwind... New members are less impacted by the STARS headwind... They have a similar margin to the existing cohort for a couple of reasons. One, the cost of acquisition... And two, a higher MLR as associated with the new members." — Celeste Mellet

MA Margin Trajectory, 2026 EPS Step-Down, and Credibility of 2028 Earnings Targets

Sentiment: Mixed

"We expect full year adjusted EPS of at least $9 with the anticipated year over year decline driven by the previous communicated bonus year 2026 STARS headwind net of mitigation... our initial guidance assumes individual MA margins are slightly below breakeven." — Celeste Mellet
"We made a set of commitments to ourselves and to investors at Investor Day last year. And we are standing by those commitments... our focus is on... getting to the right long term sustainable, durable, attractive margin... Are we focused on new member growth? No... It is great experience. It is retention, and it's getting to the right margin profile." — James Rechtin

STARS Headwind, Path Back to Top Quartile, and Impact on Profitability

Sentiment: Mixed

"The net STARS headwind for 2026 including individual and group MA, is approximately $3.5 billion... While we now have 45% of members in four plus star plans for '26, our expected membership base will also be 25% higher... Higher retention means that we kept more members on the 3.5 star contracts than we previously expected." — Celeste Mellet
"We continue to be confident that we are on the right track to return to top quartile STARS results in b y '28... This is STARS. It is a relative score. There is always risk in this... but can we say that we feel good about our ability to mitigate that risk yes, this has been very much top of mind." — James Rechtin

Medicare Advantage Funding / Rate Notice and Strategy for 2027 Bids

Sentiment: Mixed

"We are committed to always protecting our consumers the best we can, and we are very aware that we must do that within the constraints of the annual funding environment. If that funding environment cannot fully support our benefit structure, then we will adapt as we have in the past." — James Rechtin
"We have a good look at member performance by around April and then we have a better look in May... both of those views are early enough that if we need to make adjustments in the bid, we can make adjustments in the bid... our focus is on... getting to the right long term sustainable, durable, attractive margin... Are we focused on new member growth? No." — James Rechtin

Capital, Statutory Requirements, and Ability to Fund Growth While Protecting the Balance Sheet

Sentiment: Positive

"Despite expected premium growth of 40% from '24 to twenty six, our statutory capital requirements will increase by less than 20%... These improvements in capital efficiency will offset over $3 billion of growth in our capital requirements... While maintaining capital with a prudent buffer above regulatory requirements and rating agency expectation." — Celeste Mellet
"We remain comfortable with our debt to cap levels which are expected to remain largely flat year over year. We remain committed to prudent debt to capital management [and] are focused on maintaining our credit rating." — Celeste Mellet

Bull Case

Humana’s outsized MA membership growth, combined with CenterWell leverage, cost transformation, capital optimization, and a credible path back to top-quartile STARS, drives a strong recovery in MA margins and EPS toward 2028 targets.

Bear Case

Persistent STARS volatility, sub-trend MA funding, cohort integration risk, and the need to support providers and capital levels could keep MA margins depressed longer than expected and prevent Humana from achieving its 2028 earnings and margin ambitions.

Looking Ahead

With revenue growing +11.3% year-over-year, the key question is whether Humana Inc. can sustain this growth trajectory, particularly around sustainability and Profitability of Massive MA Membership Growth (incl. new cohort vs. existing, LTV, and accretion). With operating margins at -3.2%, margin trends will remain a focal point. The market's negative earnings-day reaction signals that investors need to see stronger execution, and the next earnings report will be a key catalyst for the stock.

Frequently Asked Questions

What was Humana Inc.'s revenue in Q4 2025?

Humana Inc. reported Q4 2025 revenue of $32.5B, representing a +11.3% year-over-year change.

Did Humana Inc. beat earnings expectations in Q4 2025?

The stock declined -3.3% on earnings day, suggesting the results fell short of market expectations. The current bull case centers on: Humana’s outsized MA membership growth, combined with CenterWell leverage, cost transformation, capital optimization, and a credible path back to top-quartile STARS, drives a strong recovery in MA margins and EPS toward 2028 targets.

What is the bull case for HUM stock?

The bull case for HUM centers on: Humana’s outsized MA membership growth, combined with CenterWell leverage, cost transformation, capital optimization, and a credible path back to top-quartile STARS, drives a strong recovery in MA margins and EPS toward 2028 targets.

What is the bear case for HUM stock?

The bear case for HUM centers on: Persistent STARS volatility, sub-trend MA funding, cohort integration risk, and the need to support providers and capital levels could keep MA margins depressed longer than expected and prevent Humana from achieving its 2028 earnings and margin ambitions.

How has HUM stock performed since its Q4 2025 earnings?

HUM moved -3.3% on the day of its Q4 2025 earnings report, underperforming the S&P 500 by +28.9% since earnings. Year-to-date, the stock has returned -31.5%.

Browse all 400+ earnings reports →

Learn More

Analyze HUM in Real Time

This is a static snapshot. For live financial data, AI-powered chat, and interactive earnings debates for Humana Inc. and 400+ other stocks, explore the full platform.

Open HUM on Calypso →

Calypso is an AI-powered equity research platform used by investment teams to cut earnings research time by over 80%.